Engineers Gate Manager’s AbCellera Biologics ABCL Stock Holding History

Engineers Gate Manager’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$633K	Buy	181,472 +170,269	+1,520%	+$613K	0.01%	1266
2025 Q4	$38.3K	Buy	+11,203	New	+$50K	﹤0.01%	1997
2024 Q3	–	Sell	-30,761	Closed	-$91.1K	–	2068
2024 Q2	$91.1K	Buy	+30,761	New	+$116K	﹤0.01%	1760
2023 Q3	–	Sell	-51,445	Closed	-$332K	–	1741
2023 Q2	$332K	Buy	+51,445	New	+$351K	0.01%	1263
2023 Q1	–	Sell	-74,105	Closed	-$751K	–	1605
2022 Q4	$751K	Sell	74,105 -4,144	-5%	-$47.9K	0.05%	647
2022 Q3	$774K	Buy	+78,249	New	+$859K	0.05%	559

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Engineers Gate Manager's ABCL Position: Q1 2026 in Review

Engineers Gate Manager increased its AbCellera Biologics (ABCL) stake by 1,520% in Q1 2026, buying an estimated $613K and bringing the position to 181,472 shares worth $633K. The position accounts for 0.01% of the portfolio, ranked #1266.

Engineers Gate Manager first reported a position in ABCL in Q3 2022 and has held it in 6 quarters since. The position peaked at $774K in Q3 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Engineers Gate Manager held 181,472 shares of AbCellera Biologics worth $633K as of Q1 2026.
Engineers Gate Manager bought 170,269 AbCellera Biologics shares in Q1 2026, an estimated $613K.
AbCellera Biologics made up 0.01% of Engineers Gate Manager's portfolio in Q1 2026, its #1266 holding.
Engineers Gate Manager first reported a position in AbCellera Biologics in Q3 2022 and has held it in 6 quarters since.
Engineers Gate Manager's AbCellera Biologics position peaked at $774K in Q3 2022.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.